On this precondition, we further analyzed the outcome of NSCLC patients either with different pathologic staging or histology and found that patients with RUNX3/H3K27me3 co-expression exhibited better outcome and longer OS especially in the pTNM-I NSCLC (P=0.0163, n = 68) and pTNM-I LUSC (P=0.0081, n = 25) subgroups, while no survival difference had been demonstrated in other subgroups (all P > 0.05, Figures 9(b)–9(j)). Here, RUNX3 is linked to non-small cell lung carcinoma.